Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Gains from Investment Securities (2019 - 2025)

Historic Gains from Investment Securities for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $100000.0.

  • Fulcrum Therapeutics' Gains from Investment Securities fell 9906.95% to $100000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $200000.0, marking a year-over-year decrease of 9813.9%. This contributed to the annual value of $9.4 million for FY2024, which is 619.24% down from last year.
  • Per Fulcrum Therapeutics' latest filing, its Gains from Investment Securities stood at $100000.0 for Q3 2025, which was down 9906.95% from $12.1 million recorded in Q2 2025.
  • Over the past 5 years, Fulcrum Therapeutics' Gains from Investment Securities peaked at $12.3 million during Q1 2024, and registered a low of $100000.0 during Q2 2024.
  • For the 5-year period, Fulcrum Therapeutics' Gains from Investment Securities averaged around $4.9 million, with its median value being $4.4 million (2021).
  • Examining YoY changes over the last 5 years, Fulcrum Therapeutics' Gains from Investment Securities showed a top increase of 1198231.2% in 2025 and a maximum decrease of 9906.95% in 2025.
  • Quarter analysis of 5 years shows Fulcrum Therapeutics' Gains from Investment Securities stood at $500000.0 in 2021, then skyrocketed by 1085.81% to $5.9 million in 2022, then soared by 70.5% to $10.1 million in 2023, then increased by 6.31% to $10.7 million in 2024, then tumbled by 99.07% to $100000.0 in 2025.
  • Its Gains from Investment Securities was $100000.0 in Q3 2025, compared to $12.1 million in Q2 2025 and $10.7 million in Q3 2024.